5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists.
Article Details
- CitationCopy to clipboard
Koyama H, Boueres JK, Han W, Metzger EJ, Bergman JP, Gratale DF, Miller DJ, Tolman RL, MacNaul KL, Berger JP, Doebber TW, Leung K, Moller DE, Heck JV, Sahoo SP
5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists.
Bioorg Med Chem Lett. 2003 May 19;13(10):1801-4.
- PubMed ID
- 12729668 [ View in PubMed]
- Abstract
A series of 5-aryl thiazolidine-2,4-diones containing 4-phenoxyphenyl side chains was designed, synthesized, and evaluated for PPAR agonist activities. One such compound 28 exhibited comparable levels of glucose correction to rosiglitazone in the db/db mouse type 2 diabetes animal model.
DrugBank Data that Cites this Article
- Binding Properties
Drug Target Property Measurement pH Temperature (°C) Rosiglitazone Peroxisome proliferator-activated receptor alpha IC 50 (nM) >50000 N/A N/A Details Rosiglitazone Peroxisome proliferator-activated receptor alpha EC 50 (nM) >3000 N/A N/A Details Rosiglitazone Peroxisome proliferator-activated receptor delta IC 50 (nM) >50000 N/A N/A Details Rosiglitazone Peroxisome proliferator-activated receptor delta EC 50 (nM) >3000 N/A N/A Details Rosiglitazone Peroxisome proliferator-activated receptor gamma EC 50 (nM) 20 N/A N/A Details Rosiglitazone Peroxisome proliferator-activated receptor gamma IC 50 (nM) 250 N/A N/A Details